版本:
中国

BRIEF-Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility

June 1 Protalix Biotherapeutics Inc

* Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility

* Protalix Biotherapeutics Inc - approval of SNDA allows co to convert its manufacturing facility in Carmiel, Israel, to a multi-product facility

* Protalix Biotherapeutics Inc - supplemental new drug application submitted to U.S. Food and Drug Administration has been approved by FDA

* Protalix Biotherapeutics expects conversion of the facility to multi-product facilitywill allow company to realize potentially significant operational savings

* Protalix Biotherapeutics - "conversion of facilities did not entail substantial additional capital expenditures" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐